This company listing is no longer active
OBSN Stock Overview
A biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
ObsEva SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.0012 |
| 52 Week High | CHF 0.085 |
| 52 Week Low | CHF 0.0012 |
| Beta | 0.64 |
| 1 Month Change | 0% |
| 3 Month Change | -92.50% |
| 1 Year Change | -98.15% |
| 3 Year Change | -99.96% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.99% |
Recent News & Updates
ObsEva SA (VTX:OBSN) Surges 84% Yet Its Low P/S Is No Reason For Excitement
Feb 09
Benign Growth For ObsEva SA (VTX:OBSN) Underpins Its Share Price
Dec 26Shareholder Returns
| OBSN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | 3.3% | 1.4% |
| 1Y | -98.2% | 83.7% | 10.2% |
Return vs Industry: OBSN underperformed the Swiss Biotechs industry which returned 57.4% over the past year.
Return vs Market: OBSN underperformed the Swiss Market which returned 3.6% over the past year.
Price Volatility
| OBSN volatility | |
|---|---|
| OBSN Average Weekly Movement | 42.5% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 8.0% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: OBSN's share price has been volatile over the past 3 months.
Volatility Over Time: OBSN's weekly volatility has increased from 31% to 42% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 15 | Fabien de Ladonchamps | www.obseva.com |
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA Fundamentals Summary
| OBSN fundamental statistics | |
|---|---|
| Market cap | CHF 140.61k |
| Earnings (TTM) | CHF 7.12m |
| Revenue (TTM) | CHF 17.65m |
0.0x
P/E Ratio0.0x
P/S RatioIs OBSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBSN income statement (TTM) | |
|---|---|
| Revenue | US$19.64m |
| Cost of Revenue | US$10.71m |
| Gross Profit | US$8.93m |
| Other Expenses | US$1.01m |
| Earnings | US$7.92m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | 0.068 |
| Gross Margin | 45.46% |
| Net Profit Margin | 40.34% |
| Debt/Equity Ratio | 0% |
How did OBSN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/11 20:28 |
| End of Day Share Price | 2024/05/03 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ObsEva SA is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Edward Nash | Canaccord Genuity |